We are live on ! Find out more
OM

Opaleye Management Portfolio holdings

AUM $1.1B
1-Year Est. Return 197.64%
This Fund
S&P 500
This Quarter Est. Return
+14.09%
1 Year Est. Return
+197.64%
3 Year Est. Return
+748.31%
5 Year Est. Return
+1,163.14%
10 Year Est. Return
+87,953.69%
AUM
$328M
AUM Growth
-$33M
Cap. Flow
-$50.7M
Cap. Flow %
-15.44%
Top 10 Hldgs %
48.5%
Holding
63
New
10
Increased
14
Reduced
12
Closed
20
Avg Time Held
4.7 quarters
Top 10 Avg Time Held
3 quarters
Top 20 Avg Time Held
3.9 quarters

Top Buys

Rank Stock Value
1
LXRX icon
Lexicon Pharmaceuticals
LXRX
+$8.86M
2
BHVN icon
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$8.46M
3
IRWD icon
Ironwood Pharmaceuticals
IRWD
+$5.89M
4
VRML
Vermillion, Inc.
VRML
+$4.93M
5
ARVN icon
Arvinas
ARVN
+$4.62M

Top Sells

Rank Stock Value
1
ASND icon
Ascendis Pharma A/S
ASND
+$11.2M
2
CMTA
Clementia Pharmaceuticals Inc.
CMTA
+$10.4M
3
NVTA
Invitae Corporation
NVTA
+$10.3M
4
CPRX icon
Catalyst Pharmaceutical
CPRX
+$9.31M
5
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$7.7M

Sector Composition

Rank Sector Weight
1 Healthcare 98.92%
2 Miscellaneous 1.08%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
CDXS icon
1
Codexis
CDXS
$154M
$24.9M 7.58%
1,350,000
-125,000
-8% -$2.41M
2014 Q1
21 quarters
HROW icon
2
Harrow
HROW
$1.09B
$19.2M 5.86%
2,210,000
+410,000
+23% +$2.26M
2018 Q3
3 quarters
AXGN icon
3
Axogen
AXGN
$2.18B
$17.8M 5.43%
900,000
-200,000
-18% -$4.28M
2015 Q1
17 quarters
EPZM
4
DELISTED
Epizyme, Inc
EPZM
$17.1M 5.22%
1,365,000
– –
2018 Q1
5 quarters
QURE icon
5
uniQure
QURE
$1.51B
$16M 4.88%
205,000
– –
2019 Q1
1 quarter
ODT
6
DELISTED
Odonate Therapeutics, Inc. Common Stock
ODT
$15.6M 4.75%
425,000
+100,000
+31% +$2.4M
2018 Q4
2 quarters
OCUL icon
7
Ocular Therapeutix
OCUL
$1.66B
$13M 3.96%
2,950,000
+1,050,000
+55% +$3.89M
2019 Q1
1 quarter
AMRN icon
8
Amarin Corp
AMRN
$254M
$12.5M 3.81%
32,250
– –
2017 Q4
6 quarters
BPMC icon
9
DELISTED
Blueprint Medicines
BPMC
$11.8M 3.59%
125,000
-5,000
-4% -$413K
2015 Q3
15 quarters
AVTX icon
10
Avalo Therapeutics
AVTX
$710M
$11.2M 3.41%
759
-40
-5% -$606K
2018 Q4
2 quarters
BOLD icon
11
DELISTED
Audentes Therapeutics, Inc
BOLD
$10.6M 3.23%
280,000
– –
2017 Q2
8 quarters
PTCT icon
12
PTC Therapeutics
PTCT
$5.25B
$10.2M 3.1%
226,388
+12,588
+6% +$497K
2018 Q1
5 quarters
CYTK icon
13
Cytokinetics
CYTK
$8.73B
$10.1M 3.09%
900,000
+50,000
+6% +$482K
2019 Q1
1 quarter
TGTX icon
14
TG Therapeutics
TGTX
$8.46B
$9.95M 3.03%
1,150,000
-216,062
-16% -$1.63M
2018 Q1
5 quarters
EIDX
15
DELISTED
Eidos Therapeutics, Inc. Common Stock
EIDX
$9.5M 2.89%
305,550
+105,550
+53% +$2.86M
2018 Q4
2 quarters
LXRX icon
16
Lexicon Pharmaceuticals
LXRX
$734M
$9.31M 2.84%
+1,480,000
New +$8.86M
2019 Q2
0 quarters
ETON icon
17
Eton Pharmaceutcials
ETON
$1.58B
$8.49M 2.59%
1,075,000
+310,227
+41% +$2.41M
2018 Q4
2 quarters
DNTH icon
18
Dianthus Therapeutics
DNTH
$4.56B
$7.89M 2.41%
33,438
+1,563
+5% +$386K
2018 Q2
4 quarters
TCDA
19
DELISTED
Tricida, Inc. Common Stock
TCDA
$7.7M 2.35%
195,000
+30,000
+18% +$1.06M
2018 Q3
3 quarters
DCPH icon
20
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$6.99M 2.13%
310,000
-30,000
-9% -$702K
2018 Q1
5 quarters
KYNB icon
21
Kyntra Bio
KYNB
$24.8M
$6.78M 2.07%
6,000
-2,000
-25% -$2.19M
2014 Q4
18 quarters
BHVN icon
22
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$6.57M 2%
+150,000
New +$8.46M
2019 Q2
0 quarters
CMRX icon
23
DELISTED
Chimerix, Inc.
CMRX
$6.35M 1.94%
1,470,000
+510,000
+53% +$1.57M
2016 Q1
13 quarters
XOMA icon
24
DELISTED
Xoma
XOMA
$5.94M 1.81%
400,000
– –
2017 Q1
9 quarters
ATXI icon
25
DELISTED
Avenue Therapeutics, Inc. Common Stock
ATXI
$5.86M 1.79%
827
+116
+16% +$672K
2018 Q4
2 quarters
1
2 3

Similar funds

CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
PFM
Premier Fund Managers Guildford, United Kingdom $1.1B AUM 14.42% 1-Year Est. Return
HBCM
Heron Bay Capital Management Bloomfield Hills, Michigan $1.1B AUM 11.31% 1-Year Est. Return
HAS
HBW Advisory Services Simi Valley, California $1.11B AUM 25.66% 1-Year Est. Return
AI
Aperture Investors New York $1.11B AUM 81.44% 1-Year Est. Return
TPA
Trivium Point Advisory Westport, Connecticut $1.1B AUM 28.81% 1-Year Est. Return
ZDA
Zweig-DiMenna Associates New York $1.1B AUM 171.86% 1-Year Est. Return
NW
Naviter Wealth Little Rock, Arkansas $1.1B AUM 33.28% 1-Year Est. Return

Opaleye Management's Q2 2019 Portfolio in Review

As of Q2 2019, Opaleye Management held 63 positions worth $328M, down 9.1% from $361M the previous quarter. Its ten largest holdings account for 49% of the portfolio.

Opaleye Management withdrew a net $50.7M in Q2 2019, closing 20 positions and reducing 12 holdings. Its most notable exit was Ascendis Pharma A/S, an estimated $11.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 99% a quarter earlier, followed by Miscellaneous.

Against the trend, Opaleye Management opened a new position in Lexicon Pharmaceuticals worth $9.31M.

  • Opaleye Management's largest Q2 2019 buy was Lexicon Pharmaceuticals: 1,480,000 shares worth $9.31M.
  • Opaleye Management added most to Ocular Therapeutix in Q2 2019, an estimated $3.89M increase.
  • Opaleye Management's biggest Q2 2019 reduction was Axogen, cutting an estimated $4.28M.
  • Opaleye Management fully exited Ascendis Pharma A/S in Q2 2019, selling an estimated $11.2M.
  • Opaleye Management's ten largest holdings make up 49% of its $328M portfolio in Q2 2019.
  • Opaleye Management opened 10 new positions and closed 20 in Q2 2019.
  • Opaleye Management's portfolio value fell 9.1% quarter-over-quarter to $328M.

Based on Opaleye Management's 13F filing for Q2 2019, filed 14 Aug 2019.